Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.60
+0.08 (0.76%)
At close: Oct 9, 2026, 4:00 PM EDT
10.61
+0.01 (0.09%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $20.87M in the quarter ending June 30, 2026, with 36.54% growth. This brings the company's revenue in the last twelve months to $77.23M, down -7.27% year-over-year. In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth. That makes Kura Oncology the 24,626th largest company in the world by revenue and 3,463rd in the United States.
Revenue (ttm)
$77.23M
Revenue Growth
-7.27%
P/S Ratio
12.21
Revenue / Employee
$297,019
Employees
260
Market Cap
942.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 276.79M |
| Immatics | 47.65M |
| Monte Rosa Therapeutics | 28.73M |
| Adlai Nortye Group | 18.06M |
| Aktis Oncology | 10.06M |
KURA News
- 2 days ago - Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes - GlobeNewsWire
- 7 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Kura Oncology initiated with an Overweight at JPMorgan - TheFly
- 10 days ago - Kura Oncology’s KO-7246 shows positive results as menin inhibitor in diabetes - TheFly
- 10 days ago - Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes - GlobeNewsWire
- 23 days ago - Kura Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Kura Oncology Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Kura Oncology launches Caspian Therapeutics - TheFly